Moreover, preclinical studies indicate the potential of SSTR4 agonists as treatments for anxiety and depression, possibly through normalization of dysregulated neurocircuitry (Scheich et al., 2016; Adamcyzk et al., 2021). Here, SSTR4 is linked to depressive symptom measurement.